A Better Real World Practice for Pemetrexed in First-Line Treatment of Advanced Mon-Squamous Non-Small Cell Lung Cancer

被引：0
|
作者：
Zhang, Y. [1 ]
Yan, B. [1 ]
Yang, H. [1 ]
Yang, N. [1 ]
机构：
[1] Hunan Canc Hosp, Changsha, Hunan, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
pemetrexed; Efficacy and safety; nonsquamous non-small-cell lung cancer;
D O I：
10.1016/j.jtho.2018.08.969
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.15-36
引用
收藏
页码：S627 / S627
页数：1
相关论文
共 50 条
  • [1] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [2] Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Fleeman, N.
    Bagust, A.
    McLeod, C.
    Greenhalgh, J.
    Boland, A.
    Dundar, Y.
    Dickson, R.
    Smith, C. Tudur
    Davis, H.
    Green, J.
    Pearson, M.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 47 - 53
  • [3] First-line Afatinib for Non-Small Cell Lung Cancer in Real World Practice
    Kim, Y.
    Sun, J.
    Park, K.
    Park, S. E.
    Lee, S.
    Ahn, M.
    Ahn, J. S.
    Lim, S. W.
    Lee, H.
    Cho, J. H.
    Kim, H. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2209 - S2209
  • [4] The use of pemetrexed for the first-line treatment of non-small cell lung cancer
    Silva, S.
    Colquitt, J.
    Hatton, M. Q.
    Mohanamurali, J.
    Lee, C.
    Danson, S.
    Fisher, P.
    Woll, P.
    LUNG CANCER, 2014, 83 : S13 - S13
  • [5] Clinical Study of Pemetrexed as the First-line Treatment in Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer
    Pu Xiaolin
    Wang Jun
    Li Wei
    Lu Binbin
    Wang Zhaoxia
    Yang Min
    Fan Weifei
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (04): : 205 - 209
  • [6] PEMETREXED AS FIRST-LINE TREATMENT IN COMBINATION WITH EARLY RADIOTHERAPY IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: A RETROSPECTIVE ANALYSIS
    Cai, Xuwei
    Zhang, Qin
    Yu, Wen
    Liu, Qi
    Fan, Min
    Feng, Wen
    Zhao, Weixin
    Fu, Xiaolong
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S554 - S554
  • [7] EFFICIENCY OF CISPLATIN, PEMETREXED, AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR JAPANESE ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
    Shiraishi, Yoshimasa
    Hirai, Humihiko
    Yamaguchi, Masafumi
    Morodomi, Yosuke
    Toyozawa, Ryo
    Inamasu, Eiko
    Kojo, Miyako
    Toyokawa, Gouji
    Takenaka, Tomoyoshi
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488
  • [8] Bevacizumab as first-line treatment for advanced non-small cell lung cancer
    Socinski, Mark A.
    DRUGS OF TODAY, 2008, 44 (04) : 293 - 301
  • [9] BUDGET IMPACT ANALYSIS OF FIRST-LINE TREATMENT WITH BRANDED PEMETREXED (ALIMTA) FOR ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN CHINA
    Shi, Q.
    Rajan, N.
    Davey, P.
    Davey, R.
    VALUE IN HEALTH, 2016, 19 (07) : A720 - A720
  • [10] PEMETREXED AND CARBOPLATIN VERSUS DOCETAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
    Ganju, Vinod
    Pereira, Jose
    Kim, Joo-Hang
    Magallanes, Manuel
    Lee, Dae-Ho
    Wang, Jie
    Martinez, Luis
    Barraclough, Helen
    Van Kooten, Maximiliano
    Orlando, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S417 - S418
12345